chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 79.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling of relaxation, Rash, Rash pruritic, Swollen tongue, Vasodilatation
Clinical narrative: the rash went down my legs but mostly on my arm; the same relaxation and feeling in her tongue which lasted an hour; rash on both arms; on the opposite arm of her vaccinated arm, she had a rash that itched and that went away; relaxation which felt like my blood vessels open; slight tongue enlargement; This spontaneous case was reported by a consumer and describes the occurrence of VASODILATATION (relaxation which felt like my blood vessels open), SWOLLEN TONGUE (slight tongue enlargement), RASH PRURITIC (on the opposite arm of her vaccinated arm, she had a rash that itched and that went away), RASH (rash on both arms) and RASH (the rash went down my legs but mostly on my arm) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (No relevant medical information provided).    On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021, the patient experienced VASODILATATION (relaxation which felt like my blood vessels open) and SWOLLEN TONGUE (slight tongue enlargement). On 24-Jan-2021, the patient experienced RASH PRURITIC (on the opposite arm of her vaccinated arm, she had a rash that itched and that went away). On 25-Jan-2021, the patient experienced RASH (rash on both arms) and FEELING OF RELAXATION (the same relaxation and feeling in her tongue which lasted an hour). On 28-Jan-2021, the patient experienced RASH (the rash went down my legs but mostly on my arm). On 29-Jan-2021, RASH PRURITIC (on the opposite arm of her vaccinated arm, she had a rash that itched and that went away), RASH (rash on both arms), RASH (the rash went down my legs but mostly on my arm) and FEELING OF RELAXATION (the same relaxation and feeling in her tongue which lasted an hour) outcome was unknown. At the time of the report, VASODILATATION (relaxation which felt like my blood vessels open) and SWOLLEN TONGUE (slight tongue enlargement) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No medical history provided. No concomitant medications provided. No treatment information provided
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Vaccination site pain
Clinical narrative: After getting the vaccine, I had a sore arm; Joints are hurting but that is not due to the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (After getting the vaccine, I had a sore arm) and ARTHRALGIA (Joints are hurting but that is not due to the vaccine) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination.     Concurrent medical conditions included Rheumatoid arthritis. Concomitant products included ETANERCEPT (ENBREL) for Rheumatoid arthritis, METHOTREXATE.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced VACCINATION SITE PAIN (After getting the vaccine, I had a sore arm) and ARTHRALGIA (Joints are hurting but that is not due to the vaccine). At the time of the report, VACCINATION SITE PAIN (After getting the vaccine, I had a sore arm) and ARTHRALGIA (Joints are hurting but that is not due to the vaccine) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Exposure during pregnancy, Prenatal screening test, Ultrasound foetal
Clinical narrative: got the vaccine while pregnant; This spontaneous prospective pregnancy case was reported by a dentist (subsequently medically confirmed) and describes the occurrence of EXPOSURE DURING PREGNANCY (got the vaccine while pregnant) in a 32-year-old female patient (gravida 2) who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Miscarriage (Miscarriage at 6 weeks) on 10-Oct-2020. Concomitant products included MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for an unknown indication.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on 04-Nov-2020 and the estimated date of delivery was 16-Aug-2021. On 21-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (got the vaccine while pregnant). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  eleventh week of the pregnancy. The delivery occurred on an unknown date.  On 21-Jan-2021, EXPOSURE DURING PREGNANCY (got the vaccine while pregnant) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 26-Jan-2021, Ultrasound foetal: findings unknown. On 03-Mar-2021, Prenatal screening test: normal. On 30-Mar-2021, Ultrasound foetal: (abnormal) baby normal and maternal low placenta noted.     mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient wants to register her pregnancy.   Most recent FOLLOW-UP information incorporated above includes: On 19-Apr-2021: Follow up information was received on 19-APR-2021. Added medical history (Miscarriage at 6 weeks)
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site pruritus, Injection site rash, Rash
Clinical narrative: Injection site itching; Rash; Injection site rash; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of INJECTION SITE RASH (Injection site rash), INJECTION SITE PRURITUS (Injection site itching) and RASH (Rash) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Jan-2021, the patient experienced INJECTION SITE RASH (Injection site rash). On 28-Jan-2021, the patient experienced INJECTION SITE PRURITUS (Injection site itching) and RASH (Rash). On 23-Jan-2021, INJECTION SITE RASH (Injection site rash) had resolved. At the time of the report, INJECTION SITE PRURITUS (Injection site itching) and RASH (Rash) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment included itching cream.   Reporter did not allow further contact   Most recent FOLLOW-UP information incorporated above includes: On 16-Apr-2021: NNI- Patient denied further follow-up.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Bedridden, Chills, Fatigue, Myalgia
Clinical narrative: In bed all day; Fatigue; Chills; Muscle pain; Joint pain; This spontaneous case was reported by a physician and describes the occurrence of BEDRIDDEN (In bed all day), FATIGUE (Fatigue), CHILLS (Chills), MYALGIA (Muscle pain) and ARTHRALGIA (Joint pain) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038K20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included INSULIN for an unknown indication.    On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, the patient experienced BEDRIDDEN (In bed all day), FATIGUE (Fatigue), CHILLS (Chills), MYALGIA (Muscle pain) and ARTHRALGIA (Joint pain). On 05-Feb-2021, BEDRIDDEN (In bed all day), FATIGUE (Fatigue), CHILLS (Chills), MYALGIA (Muscle pain) and ARTHRALGIA (Joint pain) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment included Tylenol; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: Tested positive for covid after first dose; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested positive for covid after first dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported.).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COVID-19 (Tested positive for covid after first dose). At the time of the report, COVID-19 (Tested positive for covid after first dose) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, SARS-CoV-2 test positive: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided No treatment information provided
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 antibody test positive
Clinical narrative: tested positive for COVID-19 after vaccination; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of SARS-COV-2 ANTIBODY TEST POSITIVE (tested positive for COVID-19 after vaccination) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event .     On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Jan-2021, the patient experienced SARS-COV-2 ANTIBODY TEST POSITIVE (tested positive for COVID-19 after vaccination). At the time of the report, SARS-COV-2 ANTIBODY TEST POSITIVE (tested positive for COVID-19 after vaccination) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 20-Jan-2021, COVID-19: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided No treatment information provided
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site induration, Injection site warmth, Vaccination site rash
Clinical narrative: Injection site was hot; Rash is a 11x9cm induration; Injection site was so red; the rash is a 11x9cm induration.; A spontaneous report was received from a HCP concerning a 66 year-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced injection site was hot/injection site warmth, Injection site was getting bigger/condition aggravated, rash is a 11x9cm induration/injection site induration and injection site was so red/injection site erythema.  The patient's medical history included two primary breast cancer, not related separate cancer, stage 2-0 and stage 1, bilateral mastectomy and bilateral lymphedema which precludes her from receiving the vaccine IM in her arms. No relevant concomitant medications were reported.    On 19 Jan 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (batch 030L20A) via an injection in the hip for prophylaxis of COVID-19 infection.  On 19 Jan 2021, the patient experienced a 11x9cm induration at the injection site, and reported the area at the injection site was red, hot and getting bigger. She consulted her primary care doctor and oncologist who prescribed treatment for the events.  Treatment for the event included 2 day prednisone taper of 40mg day 1 and 20mg day 2,  8 doses of Benadryl 25mg (4 times a day for 2 days), and the doses of doxycycline 100mg.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of the events, injection site was hot, injection site was getting bigger, rash is a 11x9cm induration and injection site was so red, were unknown.; Reporter's Comments: Based on the information provide which includes a strong temporal association, a causal association between the reported events and the administration of the mRNA-1273 cannot be excluded. injection site erythema and injection site induration are consistent with the known safety profile of the vaccine
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Dizziness, Vertigo
Clinical narrative: dizziness seems to clear up during the day; vertigo symptoms; sore shoulder; This spontaneous case was reported by a consumer and describes the occurrence of VERTIGO (vertigo symptoms), DIZZINESS (dizziness seems to clear up during the day) and ARTHRALGIA (sore shoulder) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination.     The patient's past medical history included Head injury and Dizziness.    On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Jan-2021, the patient experienced ARTHRALGIA (sore shoulder). On 24-Jan-2021, the patient experienced VERTIGO (vertigo symptoms). On 27-Jan-2021, the patient experienced DIZZINESS (dizziness seems to clear up during the day). At the time of the report, VERTIGO (vertigo symptoms) outcome was unknown and DIZZINESS (dizziness seems to clear up during the day) and ARTHRALGIA (sore shoulder) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       This case concerns a 74-year-old male who had nonserious unexpected events of vertigo, dizziness and expected arthralgia.  Event onset occurred 2 days after the first dose of mRNA-1273. Treated with meclizine. Dizziness and arthralgia resolved, but vertigo outcome unknown. Based on current available information and temporal association between the use of the product and the start date of the vertigo, dizziness and arthralgia, a causal relationship cannot be excluded.; Sender's Comments: This case concerns a 74-year-old male who had nonserious unexpected events of vertigo, dizziness and expected arthralgia.  Event onset occurred 2 days after the first dose of mRNA-1273. Treated with meclizine. Dizziness and arthralgia resolved, but vertigo outcome unknown. Based on current available information and temporal association between the use of the product and the start date of the vertigo, dizziness and arthralgia, a causal relationship cannot be excluded.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Decreased appetite, Fatigue, Headache, Lethargy
Clinical narrative: Severe body ache; fever; fatigue; no energy; no appetite; Massive headache; Mild headahe; This spontaneous case was reported by a nurse and describes the occurrence of HEADACHE (Mild headahe), MYALGIA (Severe body ache), PYREXIA (fever), FATIGUE (fatigue) and LETHARGY (no energy) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Knee surgery NOS on 13-Jan-2021. Concomitant products included APIXABAN (ELIQUIS) and PARACETAMOL (TYLENOL) for Knee surgery NOS, MULTIVITAMINS, VITAMIN B COMPLEX and VITAMIN D for an unknown indication.    On 25-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jan-2021, the patient experienced HEADACHE (Mild headahe). On 26-Jan-2021, the patient experienced MYALGIA (Severe body ache), PYREXIA (fever), FATIGUE (fatigue), LETHARGY (no energy), DECREASED APPETITE (no appetite) and HEADACHE (Massive headache). On 27-Jan-2021, HEADACHE (Mild headahe), MYALGIA (Severe body ache), PYREXIA (fever), FATIGUE (fatigue), LETHARGY (no energy), DECREASED APPETITE (no appetite) and HEADACHE (Massive headache) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 26-Jan-2021, Body temperature increased: Initially Temperature was 99.5 and the got up to 103.5.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment included Tylenol 1000mg q 6 h
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia
Clinical narrative: Severe body ache; fever; fatigue; no energy; no appetite; Massive headache; Mild headahe; This spontaneous case was reported by a nurse and describes the occurrence of HEADACHE (Mild headahe), MYALGIA (Severe body ache), PYREXIA (fever), FATIGUE (fatigue) and LETHARGY (no energy) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Knee surgery NOS on 13-Jan-2021. Concomitant products included APIXABAN (ELIQUIS) and PARACETAMOL (TYLENOL) for Knee surgery NOS, MULTIVITAMINS, VITAMIN B COMPLEX and VITAMIN D for an unknown indication.    On 25-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jan-2021, the patient experienced HEADACHE (Mild headahe). On 26-Jan-2021, the patient experienced MYALGIA (Severe body ache), PYREXIA (fever), FATIGUE (fatigue), LETHARGY (no energy), DECREASED APPETITE (no appetite) and HEADACHE (Massive headache). On 27-Jan-2021, HEADACHE (Mild headahe), MYALGIA (Severe body ache), PYREXIA (fever), FATIGUE (fatigue), LETHARGY (no energy), DECREASED APPETITE (no appetite) and HEADACHE (Massive headache) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 26-Jan-2021, Body temperature increased: Initially Temperature was 99.5 and the got up to 103.5.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment included Tylenol 1000mg q 6 h
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Administration site movement impairment, Axillary pain
Clinical narrative: arm started being acy and painful; she couldn't move it; This spontaneous case was reported by a consumer and describes the occurrence of AXILLARY PAIN (arm started being acy and painful) and ADMINISTRATION SITE MOVEMENT IMPAIRMENT (she couldn't move it) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included DIPHENHYDRAMINE HYDROCHLORIDE (ALLERGY [DIPHENHYDRAMINE HYDROCHLORIDE]) for Allergic reaction NOS, INSULIN for Diabetes.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Feb-2021, the patient experienced AXILLARY PAIN (arm started being acy and painful) and ADMINISTRATION SITE MOVEMENT IMPAIRMENT (she couldn't move it). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, AXILLARY PAIN (arm started being acy and painful) outcome was unknown and ADMINISTRATION SITE MOVEMENT IMPAIRMENT (she couldn't move it) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   It is reported that patient had hot and cold compress for treatment. Patient is taking water pill, medicine for blood pressure and medication acid reflux.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Dizziness, Oxygen saturation decreased
Clinical narrative: oxygen meter at home dropped down to 87; heaviness in my chest; dizzy; A spontaneous report was received from a consumer concerning herself a 73-years-old  female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events oxygen saturation decreased, chest discomfort, dizziness.  The patient's medical history was not provided. Concomitant medications reported were enalapril, atenolol, atorvastatin, aspirin and metformin.  On 5 Feb 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: 007M20A) intramuscularly in the left deltoid for prophylaxis of COVID-19 infection.  On 5 Feb 2021, the patient experienced the event(s) oxygen meter at home dropped down to 87, heaviness in her chest and dizzy. She called her doctor and he said she should be okay it is normal for it fluctuate.  Treatment details was not included   Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s), oxygen saturation, chest discomfort and dizziness were unknown.
Age: 83.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Influenza like illness, Myalgia
Clinical narrative: flu like symptoms; chills; fatigue; body aches; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 28-Jan-2021 and was forwarded to Moderna on 29-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (flu like symptoms), CHILLS (chills), FATIGUE (fatigue) and MYALGIA (body aches) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced INFLUENZA LIKE ILLNESS (flu like symptoms), CHILLS (chills), FATIGUE (fatigue) and MYALGIA (body aches). At the time of the report, INFLUENZA LIKE ILLNESS (flu like symptoms), CHILLS (chills), FATIGUE (fatigue) and MYALGIA (body aches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Glucose tolerance test, Maternal exposure during pregnancy, Pregnancy test, Ultrasound foetal
Clinical narrative: pregnant; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (pregnant) in a 27-year-old female patient (gravida 2) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination.     No medical history is provided and concomitant drugs are provided.  Concomitant products included ACETYLSALICYLIC ACID (ASPIRIN (E.C.)), PRENATAL + DHA and INSULIN from an unknown date to 22-Feb-2021 for an unknown indication.   On 09-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 2 dosage form. The patient's last menstrual period was on 15-Jul-2020 and the estimated date of delivery was 21-Apr-2021. On 09-Jan-2021, the patient experienced EXPOSURE DURING PREGNANCY (pregnant). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-fifth week of the pregnancy.  On 09-Jan-2021, EXPOSURE DURING PREGNANCY (pregnant) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-Aug-2020, Pregnancy test: positive (Positive) Positive. On 15-Dec-2020, Ultrasound foetal: normal (normal) Good. On 30-Jan-2021, Glucose tolerance test: abnormal (abnormal) abnormal- diagnosed with gestational diabetes.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medication was not reported. 19 May 2020 misscarriage 10 weeks was reported.    Most recent FOLLOW-UP information incorporated above includes: On 24-Feb-2021: concomitant drugs are added and patient demographics are added
Age: 83.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster, Nausea, Pain, Pruritus
Clinical narrative: Shingles; Soreness / Painful; itchy; Nauseous; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (Shingles), PAIN (Soreness / Painful), PRURITUS (itchy) and NAUSEA (Nauseous) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L20A) for COVID-19 vaccination.     No medical history information was provided.  Concomitant products included LISINOPRIL and ATORVASTATIN CALCIUM, EZETIMIBE (STATIN EZ) for an unknown indication.    On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Feb-2021, the patient experienced HERPES ZOSTER (Shingles), PAIN (Soreness / Painful), PRURITUS (itchy) and NAUSEA (Nauseous). At the time of the report, HERPES ZOSTER (Shingles), PAIN (Soreness / Painful), PRURITUS (itchy) and NAUSEA (Nauseous) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   No Treatment information provided   Most recent FOLLOW-UP information incorporated above includes: On 01-Apr-2021: No specific follow-up information recorded.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Dehydration, Diarrhoea, Migraine, Nausea
Clinical narrative: Sharp abdominal pain; Loose bowels; Pain; Nausea; Vomitting; Severe migraine; Dehydration; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of MIGRAINE (Severe migraine), DEHYDRATION (Dehydration), ABDOMINAL PAIN (Sharp abdominal pain), DIARRHOEA (Loose bowels) and PAIN (Pain) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (no medical  history reported). Concomitant products included LORAZEPAM for an unknown indication.   On 16-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Feb-2021, the patient experienced MIGRAINE (Severe migraine), DEHYDRATION (Dehydration), PAIN (Pain), NAUSEA (Nausea) and VOMITING (Vomitting). On 19-Feb-2021, the patient experienced ABDOMINAL PAIN (Sharp abdominal pain) and DIARRHOEA (Loose bowels). On 17-Feb-2021, MIGRAINE (Severe migraine), DEHYDRATION (Dehydration), PAIN (Pain), NAUSEA (Nausea) and VOMITING (Vomitting) had resolved. On 19-Feb-2021, ABDOMINAL PAIN (Sharp abdominal pain) and DIARRHOEA (Loose bowels) had resolved.            Concomitant product medications included  lorazepam and vitamin supplements.  She was treated with aluminum hydroxide, magnesium hydroxide, simethicone and discharged. Treatment provided was iv fluids, paracetmol, ondansetron; Sender's Comments: This case concerns a 58 Y/O F with nonserious unexpected events of migraine, abdominal pain, diarrhea, dehydration, pain and expected nausea, vomiting.  Event onset the same day as second dose mRNA-1273. Event resolved. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Vomiting
Clinical narrative: Sharp abdominal pain; Loose bowels; Pain; Nausea; Vomitting; Severe migraine; Dehydration; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of MIGRAINE (Severe migraine), DEHYDRATION (Dehydration), ABDOMINAL PAIN (Sharp abdominal pain), DIARRHOEA (Loose bowels) and PAIN (Pain) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (no medical  history reported). Concomitant products included LORAZEPAM for an unknown indication.   On 16-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Feb-2021, the patient experienced MIGRAINE (Severe migraine), DEHYDRATION (Dehydration), PAIN (Pain), NAUSEA (Nausea) and VOMITING (Vomitting). On 19-Feb-2021, the patient experienced ABDOMINAL PAIN (Sharp abdominal pain) and DIARRHOEA (Loose bowels). On 17-Feb-2021, MIGRAINE (Severe migraine), DEHYDRATION (Dehydration), PAIN (Pain), NAUSEA (Nausea) and VOMITING (Vomitting) had resolved. On 19-Feb-2021, ABDOMINAL PAIN (Sharp abdominal pain) and DIARRHOEA (Loose bowels) had resolved.            Concomitant product medications included  lorazepam and vitamin supplements.  She was treated with aluminum hydroxide, magnesium hydroxide, simethicone and discharged. Treatment provided was iv fluids, paracetmol, ondansetron; Sender's Comments: This case concerns a 58 Y/O F with nonserious unexpected events of migraine, abdominal pain, diarrhea, dehydration, pain and expected nausea, vomiting.  Event onset the same day as second dose mRNA-1273. Event resolved. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Pain, Tinnitus
Clinical narrative: Ringing in his ears; Headache; sore all over body like somebody just beat him up; A spontaneous report was received from a consumer concerning a 54-years-old male patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events sore all over his body like somebody just beat him up, headache, ringing in his ears.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 21 Feb 2021, prior to the onset of the events the patient received  second of two planned doses of mRNA-1273 (lot/batch: Unknown) via unknown route for prophylaxis of COVID-19 infection.  On 21 Feb 2021, the patient experienced the events sore all over his body like somebody just beat him up, headache, ringing in his ears.Consent for safety to follow up given.  Treatment details included acetaminophen and didn't help.  Action taken with mRNA-1273 in response to the events was not applicable.  The outcome of event, sore all over his body like somebody just beat him up, headache, ringing in his ears was unknown.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Chills, Cough, Fatigue, Pain in extremity
Clinical narrative: Tested positive for Covid after the 1st dose; Dry cough; little sore left arm; Chills; Felt little tired; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 27-Jan-2021 and was forwarded to Moderna on 28-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested positive for Covid after the 1st dose), COUGH (Dry cough), PAIN IN EXTREMITY (little sore left arm), CHILLS (Chills) and FATIGUE (Felt little tired) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. o41120A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ATORVASTATIN CALCIUM (LIPITOR) for an unknown indication.    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jan-2021, the patient experienced COUGH (Dry cough), PAIN IN EXTREMITY (little sore left arm), CHILLS (Chills) and FATIGUE (Felt little tired). On 26-Jan-2021, the patient experienced COVID-19 (Tested positive for Covid after the 1st dose). The patient was treated with PARACETAMOL (TYLENOL) ongoing from 25-Jan-2021 at a dose of 1 dosage form. On 27-Jan-2021, COUGH (Dry cough), PAIN IN EXTREMITY (little sore left arm), CHILLS (Chills) and FATIGUE (Felt little tired) had resolved. At the time of the report, COVID-19 (Tested positive for Covid after the 1st dose) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 26-Jan-2021, SARS-CoV-2 test positive: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The second dose of mRNA-1273 is scheduled on 15 FEB 2021.
Age: 60.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: Tested positive for Covid after the 1st dose; Dry cough; little sore left arm; Chills; Felt little tired; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 27-Jan-2021 and was forwarded to Moderna on 28-Jan-2021.    This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested positive for Covid after the 1st dose), COUGH (Dry cough), PAIN IN EXTREMITY (little sore left arm), CHILLS (Chills) and FATIGUE (Felt little tired) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. o41120A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ATORVASTATIN CALCIUM (LIPITOR) for an unknown indication.    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jan-2021, the patient experienced COUGH (Dry cough), PAIN IN EXTREMITY (little sore left arm), CHILLS (Chills) and FATIGUE (Felt little tired). On 26-Jan-2021, the patient experienced COVID-19 (Tested positive for Covid after the 1st dose). The patient was treated with PARACETAMOL (TYLENOL) ongoing from 25-Jan-2021 at a dose of 1 dosage form. On 27-Jan-2021, COUGH (Dry cough), PAIN IN EXTREMITY (little sore left arm), CHILLS (Chills) and FATIGUE (Felt little tired) had resolved. At the time of the report, COVID-19 (Tested positive for Covid after the 1st dose) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 26-Jan-2021, SARS-CoV-2 test positive: positive (Positive) Positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The second dose of mRNA-1273 is scheduled on 15 FEB 2021.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Erythema, Injection site warmth, Vaccination site pain, Vaccination site rash, Vaccination site reaction
Clinical narrative: left arm became angy red; covid arm; rash on arm was warm; rash was 3.5 inches wide and 5 inches in length, slightly raised; slightly raised rash; little sore; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of ERYTHEMA (left arm became angy red), VACCINATION SITE REACTION (covid arm), INJECTION SITE WARMTH (rash on arm was warm), VACCINATION SITE RASH (rash was 3.5 inches wide and 5 inches in length, slightly raised) and VACCINATION SITE SWELLING (slightly raised rash) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 09-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jan-2021, the patient experienced ERYTHEMA (left arm became angy red), VACCINATION SITE REACTION (covid arm), INJECTION SITE WARMTH (rash on arm was warm), VACCINATION SITE RASH (rash was 3.5 inches wide and 5 inches in length, slightly raised), VACCINATION SITE SWELLING (slightly raised rash) and VACCINATION SITE PAIN (little sore). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (topical) at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (oral) at a dose of 25 mg. At the time of the report, ERYTHEMA (left arm became angy red), VACCINATION SITE REACTION (covid arm), INJECTION SITE WARMTH (rash on arm was warm), VACCINATION SITE RASH (rash was 3.5 inches wide and 5 inches in length, slightly raised), VACCINATION SITE SWELLING (slightly raised rash) and VACCINATION SITE PAIN (little sore) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 28-May-2021: Follow-up information received on 28-May-2021 contains no new information.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site swelling
Clinical narrative: left arm became angy red; covid arm; rash on arm was warm; rash was 3.5 inches wide and 5 inches in length, slightly raised; slightly raised rash; little sore; This spontaneous case was reported by a physician (subsequently medically confirmed) and describes the occurrence of ERYTHEMA (left arm became angy red), VACCINATION SITE REACTION (covid arm), INJECTION SITE WARMTH (rash on arm was warm), VACCINATION SITE RASH (rash was 3.5 inches wide and 5 inches in length, slightly raised) and VACCINATION SITE SWELLING (slightly raised rash) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 09-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jan-2021, the patient experienced ERYTHEMA (left arm became angy red), VACCINATION SITE REACTION (covid arm), INJECTION SITE WARMTH (rash on arm was warm), VACCINATION SITE RASH (rash was 3.5 inches wide and 5 inches in length, slightly raised), VACCINATION SITE SWELLING (slightly raised rash) and VACCINATION SITE PAIN (little sore). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (topical) at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) (oral) at a dose of 25 mg. At the time of the report, ERYTHEMA (left arm became angy red), VACCINATION SITE REACTION (covid arm), INJECTION SITE WARMTH (rash on arm was warm), VACCINATION SITE RASH (rash was 3.5 inches wide and 5 inches in length, slightly raised), VACCINATION SITE SWELLING (slightly raised rash) and VACCINATION SITE PAIN (little sore) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 28-May-2021: Follow-up information received on 28-May-2021 contains no new information.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chest pain, Fatigue, Headache, Lymphadenopathy
Clinical narrative: Left sided chest pain; Some discomfort in the right shoulder/ Joint pain; Headache; Cervical lymphoadenopathy; Severe fatigue/experiencing so much fatigue that they cannot work; A spontaneous report was received from a 58-years-old  female patient who was a Healthcare Professional received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events  severe fatigue, left sided chest pain, ongoing cervical lymphadenopathy some discomfort in the right shoulder, joint pain, headaches.  The patient's medical history was not provided.   The patient past medication history included vitamins and chinese herbs for unknown indication.  No relevant concomitant medications were reported.  On 23 Jan 2021, prior to the onset of the events the patient received her first of two planned doses of mRNA-1273 (lot/batch: 025J20-2A) via unknown route at unknown anatomical location for prophylaxis of COVID-19 infection.  On 23 Jan 2021, the patient experienced the events had severe fatigue/so much fatigue that cannot work, when she was walking she got exhausted, left sided chest pain, ongoing cervical lymphadenopathy that comes and goes, some discomfort in the right shoulder, Joint pain and headaches all of that had gone about the fifth or sixth day. The patient was taking supplements (vitamins and chinese herbs) before taking the vaccine but stopped after because she was confused about the cause of the symptoms.  Treatment details included None.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s) headaches, joint pain was considered resolved on 29 Jan 2021.  The outcome of events has severe fatigue/so much fatigue that cannot work, when she was walking she got exhausted, left sided chest pain, ongoing cervical lymphadenopathy that comes and goes, some discomfort in the right shoulder was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Myalgia, Nausea, Pyrexia, Somnolence
Clinical narrative: Felt like sleeping all day; Rash; Fever; Muscle pain; chills; Nausea; A spontaneous report was received from a consumer concerning a 77-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events fever, muscle pain, chills, nausea and somnolescence.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 21 Jan 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: 029L20A) intramuscularly in the right arm for prophylaxis of COVID-19 infection.  On 22 Jan 2021, the patient experienced the event(s) fever, muscle pain, chills, nausea and felt like sleeping all day.  Treatment details included Tylenol.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s), fever, muscle pain, chills, nausea  and somnolescence was unknown. Rash coded to Vaccination site rash.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site rash
Clinical narrative: Felt like sleeping all day; Rash; Fever; Muscle pain; chills; Nausea; A spontaneous report was received from a consumer concerning a 77-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events fever, muscle pain, chills, nausea and somnolescence.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 21 Jan 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot/batch: 029L20A) intramuscularly in the right arm for prophylaxis of COVID-19 infection.  On 22 Jan 2021, the patient experienced the event(s) fever, muscle pain, chills, nausea and felt like sleeping all day.  Treatment details included Tylenol.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s), fever, muscle pain, chills, nausea  and somnolescence was unknown. Rash coded to Vaccination site rash.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Swelling
Clinical narrative: lump; ymph node that is swelling; A spontaneous report was received from a Healthcare Professional Dear concerning a 40-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events a lump, (lump) kind of swelling under her collar bond near her on left shoulder.she is assuming is it her, little hard to touch.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 26 Jan 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot batch: 012L20A) intramuscularly for prophylaxis of COVID-19 infection.  On 27 Jan 2021, the patient experienced the events a lump. (lump) kind of swelling under her collar bond near her on left shoulder. She is assuming is it her, little hard to touch.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   On an unknown date the outcome of events include, a lump, (lump) kind of swelling under her collar bond near her on left shoulder. she is assuming is it her, little hard to touch was not reported.  Based on comment Lump is coded as Subclavicular lymphadenopathy
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pain, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: itching; a little bit of swelling; redness; a little bit of tenderness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (itching), VACCINATION SITE SWELLING (a little bit of swelling), VACCINATION SITE ERYTHEMA (redness) and VACCINATION SITE PAIN (a little bit of tenderness) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event. Concomitant products included Premarin                                                       had a hysterectomy, LEVOTHYROXINE, Sumatriptan                                                    for migraines, Rizatriptan                                                    alternative for migraines, butalbital/ acetaminophen/ caffeine                            alternative for migraines, CALCIUM CARBONATE, COLECALCIFEROL (VITAMIN D 2000), ASCORBIC ACID, ROSA CANINA FRUIT (VITAMIN C & ROSEHIP) and CALCIUM for an unknown indication.    On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, the patient experienced VACCINATION SITE PRURITUS (itching), VACCINATION SITE SWELLING (a little bit of swelling), VACCINATION SITE ERYTHEMA (redness) and VACCINATION SITE PAIN (a little bit of tenderness). At the time of the report, VACCINATION SITE PRURITUS (itching), VACCINATION SITE SWELLING (a little bit of swelling), VACCINATION SITE ERYTHEMA (redness) and VACCINATION SITE PAIN (a little bit of tenderness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment details included Had some benadryl cream (but it was expired).